Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

Detalles Bibliográficos
Autores principales: Proskorovsky, Irina, Vandendries, Erik, Pagé, Véronique, Cappelleri, Joseph C., Stelljes, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004421/
https://www.ncbi.nlm.nih.gov/pubmed/31838711
http://dx.doi.org/10.1007/s12325-019-01169-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004421/
https://www.ncbi.nlm.nih.gov/pubmed/31838711
http://dx.doi.org/10.1007/s12325-019-01169-0

Ejemplares similares